Huntington’s Disease Treatment Industry Forecasted for Rapid Expansion, Reaching $1.32 Billion by 2029
Unlock 20% Off Global Market Reports Using Code ONLINE20 – Stay Informed on Trade Policies, Market Growth, and Key Disruptors
How Is the Huntington’s Disease Treatment Market Growth Forecast from 2025 to 2029?
The Huntington’s disease treatment market size has grown rapidly in recent years. It will grow from $0.73 billion in 2024 to $0.82 billion in 2025 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to increasing awareness of genetic disorders, growing genetic testing accessibility, growing investment in neurodegenerative disease research, a rising number of clinical trials for experimental therapies, and a growing pipeline of disease-modifying drugs.
The Huntington’s disease treatment market size is expected to see rapid growth in the next few years. It will grow to $1.32 billion in 2029 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to a growing focus on personalized medicine, increasing integration of digital health monitoring, increasing regulatory support for orphan drugs, rising demand for symptomatic relief therapies, and growing demand for disease-modifying treatments. Major trends in the forecast period include technology-driven gene silencing tools, developing cell-based therapies, developing peripheral biomarkers, integration of telehealth in HD care, integration of patient-reported outcomes, and innovation in disease-modifying drugs.
Claim your free report sample now:
Which Major Growth Factors Are Shaping the Huntington’s Disease Treatment Market?
The increase in gene therapies is expected to propel the growth of the Huntington’s disease treatment market going forward. Gene therapies are treatments that modify or replace faulty genes to cure or prevent diseases at the genetic level. Gene therapies are growing as precision medicine advances, enabling direct targeting of genetic causes and achieving better outcomes than traditional treatments. Gene therapies treat Huntington’s disease by silencing the defective HTT gene that generates harmful proteins, preventing nerve cell damage. This strategy helps slow disease progression, protect brain function, and offers potential for long-term control. For instance, in July 2023, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, at the end of Q1 2023, there were 247 gene therapies in phase II, but this number rose by 5% to reach 260 by the end of Q2. Therefore, the increase in gene therapies is driving the growth of the Huntington’s disease treatment market.
Which Segment Offers the Highest Growth Opportunities in the Huntington’s Disease Treatment Market?
The huntington’s disease treatment market covered in this report is segmented –
1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies
2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical
3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers
Subsegments:
1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers
2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies
How Are Innovation and Technology Shaping the Future Trends of the Huntington’s Disease Treatment Market?
Major companies operating in the Huntington’s disease treatment market are focused on developing advanced therapies such as selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules to potentially improve patient quality of life while slowing disease progression. Selective VMAT2 inhibitor capsules are medications that block the vesicular monoamine transporter 2, a protein involved in packaging neurotransmitters for brain release. These drugs help reduce neurotransmitter release, aiding in the management of involuntary movements and related symptoms. For instance, in August 2023, Neurocrine Biosciences, Inc., a US-based biotech company, received approval from the U.S. Food and Drug Administration (FDA) for Ingrezza (valbenazine) capsules for the treatment of chorea associated with Huntington's disease (HD) in adults. These capsules are a once-daily oral VMAT2 inhibitor, working by reducing excessive dopamine signaling in the brain to help control involuntary movements. The medication is available in multiple capsule strengths and can be taken with or without food, offering a convenient dosing option for patients.
Who Are the Key Players Driving the Huntington’s Disease Treatment Market?
Major companies operating in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Bausch Health Companies Inc., Sun Pharmaceutical Industries Inc., H. Lundbeck A/S, WaVe Life Sciences Ltd., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Annexon Inc., Uniqure NV, Sage Therapeutics Inc., Azevan Pharmaceuticals Inc., Prilenia Therapeutics B.V.
Get the full huntington’s disease treatment market report here:
What Are the Regional Insights for the Huntington’s Disease Treatment Market Forecast?
North America was the largest region in the Huntington’s disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment